Skip to main navigation Skip to search Skip to main content

Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer

  • Paul Ritch
  • , Charles M. Rudin
  • , Jacob David Bitran
  • , Martin J. Edelman
  • , Alex Makalinao
  • , David Irwin
  • , Rogerio Lilenbaum
  • , Patrick Peterson
  • , William J. John
  • Medical College of Wisconsin
  • University of Chicago
  • Advocate Health Care
  • University of Maryland Cancer Center
  • California Hematology Oncology Medical Group
  • Alta Bates Comprehensive Cancer Center
  • Mount Sinai Medical Center Miami Beach
  • Eli Lilly and Company
  • Commonwealth Cancer Center

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science